Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Lignende værker

• Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
  af: Greenfield, Graeme, et al.
  Udgivet: (2019)
• BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
  af: Cai, Zhimei, et al.
  Udgivet: (2020)
• BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
  af: Sherbenou, Daniel W., et al.
  Udgivet: (2010)
• Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?
  af: Bonecker, Simone, et al.
  Udgivet: (2015)
• Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript
  af: Tchirkov, Andrei, et al.
  Udgivet: (2006)